Zobrazeno 1 - 10
of 185
pro vyhledávání: '"Jose Maria Pacheco"'
Publikováno v:
São Paulo Medical Journal, Vol 113, Iss 2 suppl, Pp 24-24
Externí odkaz:
https://doaj.org/article/98214002bd48417dbba1d156deff0d5d
Autor:
Nascimento, Viviane Gabriela, Schoeps, Denise de Oliveira, Souza, Sônia Buongermino de, Souza, José Maria Pacheco de, Leone, Claudio
Publikováno v:
In Revista da Associação Médica Brasileira November-December 2011 57(6):657-661
Autor:
Alexander I. Spira, Gregory J. Riely, Shirish M. Gadgeel, Rebecca Suk Heist, Sai-Hong Ignatius Ou, Jose Maria Pacheco, Melissa Lynne Johnson, Joshua K. Sabari, Konstantinos Leventakos, Edwin Yau, Lyudmila Bazhenova, Marcelo Vailati Negrao, Nathan A. Pennell, Jun Zhang, Karen Velastegui, James G Christensen, xiaohong yan, Kenna Lynn Anderes, Richard C. Chao, Pasi A. Janne
Publikováno v:
Journal of Clinical Oncology. 40:9002-9002
9002 Background: KRAS is a key mediator of the RAS/MAPK signaling cascade that promotes cellular growth and proliferation. KRASG12C mutation occurs in ̃14% of NSCLC. Adagrasib, an investigational agent, is a KRASG12C inhibitor that irreversibly and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9188386804b27bfbb4981eb65c487616
https://doi.org/10.1200/jco.2022.40.16_suppl.9002
https://doi.org/10.1200/jco.2022.40.16_suppl.9002
Autor:
Melissa Lynne Johnson, Grace K. Dy, Hirva Mamdani, Afshin Dowlati, Adam Jacob Schoenfeld, Jose Maria Pacheco, Rachel E. Sanborn, Smitha Patiyil Menon, Linda Santiago, Yifah Yaron, Himisha Beltran
Publikováno v:
Journal of Clinical Oncology. 40:8566-8566
8566 Background: HPN328 is a delta like canonical Notch ligand 3 (DLL3)-targeting T-cell engager (TCE) derived from the TriTAC platform, designed to minimize off-target toxicities. HPN328 contains 3 binding domains, engineered to redirect T cells to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b466d4fd30707ad081034e31174b4b0d
https://doi.org/10.1200/jco.2022.40.16_suppl.8566
https://doi.org/10.1200/jco.2022.40.16_suppl.8566
Autor:
Tejas Patil, William T. Purcell, D. Ross Camidge, Paul A. Bunn, Jose Maria Pacheco, Andrew Nicklawsky, David Chun Cheong Tsui, Erin L. Schenk
Publikováno v:
Journal of Clinical Oncology. 39:9124-9124
9124 Background: Continuing a 1st generation EGFR TKI with chemotherapy upon TKI progression was not shown to be beneficial in the IMPRESS trial. However, the validity of this approach with osimertinib remains under explored. We attempted to characte
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f4f2e4144f83a92eb285b1ef5684ac53
https://doi.org/10.1200/jco.2021.39.15_suppl.9124
https://doi.org/10.1200/jco.2021.39.15_suppl.9124
Autor:
Paul A. Bunn, Junxiao Hu, Jose Maria Pacheco, William T. Purcell, Yunan Nie, Erin L. Schenk, D. Ross Camidge, Tejas Patil
Publikováno v:
Journal of Clinical Oncology. 39:e21205-e21205
e21205 Background: Use of maintenance pemetrexed with pembrolizumab is the standard of care among patients with metastatic nonsquamous NSCLC without EGFR or ALK alterations treated with the KEYNOTE-189 regimen. Whether the addition of pembrolizumab t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b3483e16a0e0461d3d0c42bc78a931aa
https://doi.org/10.1200/jco.2021.39.15_suppl.e21205
https://doi.org/10.1200/jco.2021.39.15_suppl.e21205
Autor:
William T. Purcell, Erin L. Schenk, Sydney Marsh, Robert C. Doebele, Tejas Patil, Rao Mushtaq, Miheer Pujara, Paul A. Bunn, Dara L. Aisner, Jose Maria Pacheco, Christine Azelby, D. Ross Camidge
Publikováno v:
Journal of Clinical Oncology. 37:9090-9090
9090 Background: The clinicopathologic characteristics and optimal treatment strategies for non-sensitizing EGFR ( ns- EGFR) and HER2 activating mutations in NSCLC remain unclear. Methods: Single-center retrospective study of patients seen at Univers
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::378dd013ba8d1eb07ced2144826a4103
https://doi.org/10.1200/jco.2019.37.15_suppl.9090
https://doi.org/10.1200/jco.2019.37.15_suppl.9090
Autor:
José Maria Pacheco de Souza
Publikováno v:
Revista Brasileira de Cancerologia, Vol 26, Iss 1 (2023)
Em estudos epidemiológicos a expressão sobrevida tem sentido bem amplo. Para câncer, por exemplo, sobrevida após o diagnóstico pode ser a quantidade de anos (ou meses, ou dias) que um paciente permanece vivo após um diagnóstico (clínico ou ra
Externí odkaz:
https://doaj.org/article/d1a5c807fb1047af9edb73a21e8780ec
Autor:
Teixeira, Andrea Mariana Nunes da Costa, Luzia, Liania Alves, de Souza, Suelen Jorge, de Almeida Petrilli, Aline, Pontilho, Patrícia de Moraes, de Souza, Jose Maria Pacheco, Segurado, Aluísio Augusto Cotrim, Efraim, Priscila, Picone, Camila de Melo, Rondo, Patrícia Helen de Carvalho
Publikováno v:
Food & Function; Jul2017, Vol. 8 Issue 6, p2212-2219, 8p
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.